- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04406909
Rapid-Cycle Re-Implementation of TRAining Facilities in Norway (TRAiN)
This study tests the randomized re-opening of training facilities in Norway in relation to the COVID-19 pandemic. The investigators will use the recently developed concept of rapid-cycle randomized implementation to assure fast and safe re-introduction of training facilities by randomized testing of access restriction and measure virus exposure and immunity as well as clinical disease during the intervention to enable safe and timely downgrading of COVID-19 restrictions.
Members of training facilities in Norway age 18 to 64 years without COVID-19 related comorbidity will after informed consent be randomised to either access to training or no access in a first 2-week cycle. Testing for COVID-19 and ascertainment of clinical disease will be performed after the first cycle. If there is no clinically meaningful difference between the arms, new cycles may be implemented subsequently, e.g. with less distancing restrictions or wider age groups.
Studieoversikt
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Oslo, Norge, 0218
- SATS Training
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
all members of participating training facilities age 18 years or older who are not at increased risk for severe COVID-19 disease (see www.fhi.no for criteria) are eligible for participation if they
- plan to use the training facility regularly during the project period
- are willing to adhere to training policies during the project
- accept assessment of project endpoints
- approve handling of data for the project
Exclusion Criteria:
- COVId-19 related comorbidity
- Age below 18 years or above 64 years
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Training
Access to training at membership training facility
|
Access to training facility under national regulations for COVID control
|
Ingen inngripen: No training
No access to training at membership training facility
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
COVID-19 RNA test positivity
Tidsramme: At the end of Cycle 1 (cycle length is 14 days)
|
Percentage of COVID-19 RNA positive individuals
|
At the end of Cycle 1 (cycle length is 14 days)
|
Hospital admission for COVID-19
Tidsramme: 7 days after the end of Cycle 1 (cycle length is 14 days)
|
Percentage of people admitted to hospital for COVID-19
|
7 days after the end of Cycle 1 (cycle length is 14 days)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
individuals with COVID-19 antibodies
Tidsramme: 14 to 20 days after the end of Cycle 1 (cycle length is 14 days)
|
Percentage of individuals with COVID-19 antibodies by blood sampling
|
14 to 20 days after the end of Cycle 1 (cycle length is 14 days)
|
Percentage of individuals with health care contacts
Tidsramme: 7 days and 3 months after the end of Cycle 1 (cycle length is 14 days)
|
Percentage of people who had any contacs with primary or secondary health care services
|
7 days and 3 months after the end of Cycle 1 (cycle length is 14 days)
|
Need of ventilator treatment after hospital admission for COVID-19
Tidsramme: 7 days and 3 months after the end of Cycle 1 (cycle length is 14 days)
|
Percentage of people in need of ventilator after hosital admission for COVID-19
|
7 days and 3 months after the end of Cycle 1 (cycle length is 14 days)
|
ICU admission for COVID-19
Tidsramme: 7 days and 3 months after the end of Cycle 1 (cycle length is 14 days)
|
Percentage of people admitted to the ICU for COVID-19
|
7 days and 3 months after the end of Cycle 1 (cycle length is 14 days)
|
Cause-specific death
Tidsramme: 7 days and 3 months after the end of Cycle 1 (cycle length is 14 days)
|
Percentage of people who died, with cause of death (including underlying cause of death)
|
7 days and 3 months after the end of Cycle 1 (cycle length is 14 days)
|
COVID-19 RNA test positivity in employees at training centres
Tidsramme: At the end of Cycle 1 (cycle length is 14 days)
|
Percentage of COVID-19 RNA positive employees who worked at the training centres during the intervention
|
At the end of Cycle 1 (cycle length is 14 days)
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Magnus Løberg, MD PhD, University of Oslo
- Hovedetterforsker: Mette Kalager, MD PhD, University of Oslo
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- REK 143984
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Opplæring
-
Center for Social Innovation, MassachusettsColumbia University; Hunter College of City University of New YorkFullførtHjemløsetjenester | Human Services TrainingForente stater
-
Riphah International UniversityRekrutteringIntegrert motstandstrening | Isolert Resised TrainingPakistan
-
Autism SpeaksUniversity of California, Los Angeles; Vanderbilt University; Hugo W. Moser...FullførtJoint Engagement + Enhanced Milieu Training | Joint Engagement + Enhanced Milieu Training + Augmentative Communication (AAC)Forente stater
-
Methodist Health SystemPåmelding etter invitasjonMock Code Training SimuleringForente stater
-
Cardenal Herrera UniversityHar ikke rekruttert ennåMotoriske bilder | Åndedrettsfunksjon | Action Observation Training
-
University of ThessalyFullførtStyre | Speed Endurance Training Protocol 1 | Speed Endurance Training Protocol 2Hellas
-
Copenhagen Academy for Medical Education and SimulationFullført
-
University of ThessalyAvsluttetPower Training Exercise ProtocolsHellas
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityHar ikke rekruttert ennåAksial forlengelse | Ungdom og barn | Naked Eye 3D Vision Training | Visuell funksjon
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityHar ikke rekruttert ennåPostoperativt delirium | Preoperativ Olfactory Training
Kliniske studier på Access to training facility
-
University of MinnesotaNational Institute on Aging (NIA)Rekruttering
-
Mental Health Services in the Capital Region, DenmarkCopenhagen Trial Unit, Center for Clinical Intervention Research; Center...FullførtPasienter med ultrahøy risiko for psykoseDanmark